Holocene

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
четверг, мая 9, 2024
ENDO, Defecation, FDA, Holocene, Investment, CAH, Safety, NDA, Pharmacokinetics, Food, Carcinoid syndrome, Research, Acromegaly, Conference, Webcast, Congenital adrenal hyperplasia, Endocrine system, Therapy, Patient, Cushing's disease, SAN, End, Pharmaceutical industry

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • ET Today
    SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2024.
  • “Building on the positive momentum from the first PATHFNDR readout in 2023, Crinetics began 2024 with continued strong performance.
  • We plan to report initial results from a subset of patients from these trials in the second quarter,” continued Dr. Struthers.
  • In March, Crinetics reported positive topline results from its placebo-controlled Phase 3 study of paltusotine in non-pharmacologically treated participants with acromegaly.

Armada Hoffler Reports First Quarter 2024 Results

Retrieved on: 
четверг, мая 9, 2024
Holocene, Investment, FFO, Ratio, OP, GAAP, Security (finance)

VIRGINIA BEACH, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Armada Hoffler Properties, Inc. (NYSE: AHH) today announced its results for the quarter ended March 31, 2024 and provided an update on current events and earnings guidance.

Key Points: 
  • VIRGINIA BEACH, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Armada Hoffler Properties, Inc. (NYSE: AHH) today announced its results for the quarter ended March 31, 2024 and provided an update on current events and earnings guidance.
  • Maintained the Company's previous guidance range for 2024 full-year Normalized FFO of $1.21 to $1.27 per diluted share.
  • Third-party construction backlog as of March 31, 2024 was $343.4 million and construction gross profit for the first quarter was $4.1 million.
  • During the first quarter of 2024, unrealized gains on non-designated interest rate derivatives that positively affected FFO were $6.5 million.

Brightcove Announces Financial Results for First Quarter Fiscal Year 2024

Retrieved on: 
среда, мая 8, 2024
Content Marketing, Online, Technology, Public Relations, Investor Relations, Audio, Video, Marketing, Advertising, Communications, General Entertainment, Apps, Applications, TV and Radio, Entertainment, Digital Marketing, Networks, Internet, Cloud, Sale, CFO, EverQuote, Holocene, News, Red, Constant Contact, Partnership, Netball Australia, Public expenditure, BCOV, IPO, Ironman, NuoDB, Eastern Time Zone, Inc., Little League Baseball, GAAP, Growth, Video game

Brightcove Inc. (Nasdaq: BCOV), the world’s most trusted streaming technology company, today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Brightcove Inc. (Nasdaq: BCOV), the world’s most trusted streaming technology company, today announced financial results for the first quarter ended March 31, 2024.
  • First Quarter 2024 Financial Highlights:
    Revenue for the first quarter of 2024 was $50.5 million, an increase of 3% compared to $49.1 million for the first quarter of 2023.
  • Income (loss) from operations was $2.0 million for the first quarter of 2024, compared to ($10.7) million for the first quarter of 2023.
  • Brightcove earnings will be streamed on May 8, 2024, at 5:00 p.m. (Eastern Time) to discuss the Company's financial results and current business outlook.

Biden-Harris Administration Announces Major Steps to Stand Up Landmark American Climate Corps Initiative, Mobilizing the Next Generation of Climate Leaders

Retrieved on: 
понедельник, апреля 22, 2024
Interior, FDR, Partnership, Human, Labour, Civilian Conservation Corps, Commerce, Ministry of home affairs, Forestry, Prince, Hand, Prince William Forest Park, Workforce, Employment, Volunteering, Public sector, Climate change, Holocene, EPA, AmeriCorps VISTA, Primary energy, Organization, ACC, History, Curriculum, Environment, AmeriCorps, Renewable energy

AmeriCorps , the federal agency for national service, serves as the hub for the American Climate Corps.

Key Points: 
  • AmeriCorps , the federal agency for national service, serves as the hub for the American Climate Corps.
  • Nearly a century after FDR established the Civilian Conservation Corps, President Biden will announce today that Americans can now apply to join the American Climate Corps through a newly launched website, ClimateCorps.gov .
  • The website, which is launching in its beta form, will be regularly updated with new American Climate Corps positions.
  • The first class of the American Climate Corps will be deployed to communities across the country in June 2024.

SBA Statement on Biden-Harris Administration Exceeding Small Disadvantaged Business Contracting Goal

Retrieved on: 
пятница, апреля 12, 2024
CHIPS, Science, Administration, Small business, Holocene, Development aid, Category management, SBA, Federal, Human, Federation, Policy, Senior, Acquisition, KEGG, Participation, Pharmaceutical industry

In January 2024, the Biden-Harris Administration announced a bold goal of increasing the share of federal contracting dollars going to SDBs to 15% by FY2025, a 50% increase from spending levels when he first took office.

Key Points: 
  • In January 2024, the Biden-Harris Administration announced a bold goal of increasing the share of federal contracting dollars going to SDBs to 15% by FY2025, a 50% increase from spending levels when he first took office.
  • As part of President Biden’s agenda , the SBA has announced new and improved initiatives to advance this goal – and we’re already seeing results.
  • “Today’s announcement shows the results, with a new record of contract spending with Small Disadvantaged Businesses and steady progress towards President Biden’s goal of awarding 15% of federal contracting dollars to Small Disadvantaged Businesses by FY2025.
  • The new procedures increase contracting opportunities for 8(a)-certified SDBs to ensure more equitable access to federal contracting dollars.

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 

Retrieved on: 
среда, апреля 10, 2024
Komodo, Psoriatic arthritis, Arthropathy, Holocene, HS, Skin, Hidradenitis suppurativa, Partnership, Research, Literature, Entrepreneurship, Disease, Steroid, Patient, Inflammation, Marketing, Moonlake, Prevalence, Pharmaceutical industry

San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.

Key Points: 
  • San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.
  • Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision making across its clinical operations, medical, marketing, and market access teams.
  • Komodo’s data and technology applications will support MoonLake’s in-depth market research, clinical trial site selection, go-to-market strategies, and patient journey mapping – all aimed at accelerating the development of new treatment options and improving outcomes for patients with inflammatory skin and joint diseases.
  • Tino Anthamatten, VP Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors.

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

Retrieved on: 
среда, апреля 10, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Artificial Intelligence, Other Science, Other Technology, Research, Software, General Health, Health Technology, Science, Data Management, Komodo, Psoriatic arthritis, Arthropathy, Holocene, HS, Skin, Hidradenitis suppurativa, Marketing, Partnership, Literature, Entrepreneurship, Disease, Steroid, Patient, Inflammation, Multimedia, Moonlake, Prevalence, Pharmaceutical industry

MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.

Key Points: 
  • MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.
  • View the full release here: https://www.businesswire.com/news/home/20240410438883/en/
    Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision-making across its clinical operations, medical, marketing, and market access teams.
  • Tino Anthamatten, VP, Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors.
  • The real-world insights from Komodo helped validate a future HS market size projected to exceed $10B by 2035.

Recent inflation developments and wage pressures in the euro area and the United States

Retrieved on: 
четверг, апреля 25, 2024
Momentum, Federal Reserve Bank, Statistics, Employment, CPI, Growth, Tourism, ECB, Unemployment, Blog, PCE, COVID-19, Common, Coronavirus, Diffusion, Holocene, PCCI, Classification, Tobacco, Food, HICP, Federal Reserve, United, Foodservice, Annual report, GDP, Spelman College, Money, Persistent, Federal, Cryptocurrency

Core inflation remains elevated overall in both economic areas, due notably to high levels of services inflation.

Key Points: 
  • Core inflation remains elevated overall in both economic areas, due notably to high levels of services inflation.
  • Labour costs started moderating earlier in the United States, with euro area wage growth peaking later and productivity growth being muted by cyclical and structural factors.

Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
четверг, марта 28, 2024
Consultant, CRH, Ovarian cancer, Conference call, Conference, Survival, Science, Intelligence, Drug discovery, Webcast, BIO, Research, Holocene, UPMC, KOL, G&A, Call, GMP, UPMC Magee-Womens Hospital, Cloud computing, CLIA, Drug development, Machine learning, Marketing, Artificial intelligence, Cryptocurrency

The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023.

Key Points: 
  • The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023.
  • “Perhaps most notably, we announced last quarter that we successfully delivered the results of our first campaign with Cancer Research Horizons.
  • Revenues for the years ended December 31, 2023, and December 31, 2022, were primarily derived from its Eagan operating segment.
  • Conference call and webcast details:
    Predictive Oncology management will host an investor conference call and webcast on Monday, April 1st, at 8:30am EDT.

Healthier Choices Management Corp. Reports Fourth Quarter 2023 Financial Results and Full Year Fiscal 2023 Results

Retrieved on: 
среда, марта 27, 2024
OTC Markets Group, Holocene, Acquisition

HOLLYWOOD, FL, March 27, 2024 (GLOBE NEWSWIRE) -- Healthier Choices Management Corp. (OTC Pink: HCMC) today announced financial results for the fourth quarter and the twelve-months ended December 31, 2023.

Key Points: 
  • Fourth Quarter 2023 Results and Recent Highlights:
    Net sales from operations for the three-month period ended December 31, 2023, amounted to $15.9 million, compared to $12.3 million, an approximately $3.5 million and 29% increase versus the same period in 2022.
  • Net Loss from Operations for the three-month period ended December 31, 2023, amounted to approximately $9.4 million versus a $3.8 million loss for the same period last year.
  • Adjusted EBITDA for the fourth quarter amounted to a loss of $1.8 million versus a $3.3 million loss for the same period in 2022, an improvement of approximately $1.5 million.
  • The following table sets forth our Condensed Consolidated Statements of Operations for the three and twelve-months ended December 31, 2023 and 2022: